相关实验视频

Updated: Jun 4, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

利图西马布在原发性IgA脏病中的有效性和安全性:一项回顾性研究

Jingzhen Li¹, Zhenyu Nie¹, Guofu Li¹

¹Department of Nephrology, Ningbo Yinzhou Second Hospital, No. 998, North Qianhe Road, Yinzhou District, Ningbo City, 315000, Zhejiang Province, China.

Clinical and experimental nephrology

|December 27, 2024

概括

利图西马布 (RTX) 改善了IgA脏病 (IgAN) 患者的血清白蛋白和减少蛋白尿. 虽然功能没有显著变化,但RTX可能为那些对其他疗法不耐受的人提供替代治疗.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

初级IgA脏病 (IgAN) 是一种常见的淋巴细胞疾病.
目前的治疗方法,如葡萄糖皮质类药物有局限性和副作用.
需要对Igan进行替代治疗选择.

研究的目的:

评估Rituximab (RTX) 在患有原发性IgA病的患者的疗效和安全性.
评估RTX对IGAN临床标记物的影响.
确定RTX作为IGAN替代治疗的潜力.

主要方法:

对22名接受RTX治疗的初级IGAN患者的回顾性审查.
分析临床数据,包括血清白蛋白,肌素,蛋白尿和eGFR在基线和3,6,12个月.
在RTX治疗期间记录和评估不良事件.

主要成果:

3个月后血清白蛋白水平显著增加 (P<0.01).
在12个月内显著降低了微专尿和尿与肌素的比率 (P<0.01).
总体缓解率为50% (2个完全,11个部分);血清肌素或EGFR没有显著变化.

结论:

利图西马布 (RTX) 在改善血清白蛋白和减少蛋白尿症方面表现出显著的疗效.
虽然没有统计学意义,但观察到改善功能的趋势.
对于不能耐受葡萄糖皮质类药物或其他免疫抑制剂的初级Igan患者来说,RTX可能是一种可行的替代治疗方法.

关键词:

在IgA脏病发作中,IgA脏病发作蛋白质尿症是一种蛋白质尿症.功能功能功能追溯研究是一项回顾性研究.里图西马布 (Rituximab) 是一种药物.

更多相关视频

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...